| Document |
Document Title |
|
WO/2024/069179A1 |
The invention relates to the treatment of nontuberculous mycobacterial infections. In particular, the invention relates to the use of prostanoid receptor modulators to treat nontuberculous mycobacterial infections.
|
|
WO/2024/062127A1 |
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispe...
|
|
WO/2024/061474A1 |
The present invention relates to products and methods for the treatment and/or prevention of neurological disorders characterized by neurodegeneration. More particularly, the invention provides a product comprising: (i) a Rho-associated ...
|
|
WO/2024/061305A1 |
The present invention provides an antibody-drug conjugate and use thereof. The antibody-drug conjugate has a structure represented by formula I, namely Ab-(L-D)p, wherein Ab is an anti-GPC3 antibody, L is a linker, and D is a cytotoxin. ...
|
|
WO/2024/012569A9 |
The present disclosure relates to the biopharmaceutical field, in particular, to a linker for preparing targeting molecule-drug conjugates, and the corresponding conjugates, the preparing process and use thereof.
|
|
WO/2024/064536A1 |
The present invention includes a method of reducing or eliminating a cardiotoxic or cardiopathic effect of one or more active agents comprising: administering to a subject in need thereof an effective amount of one or more lipids that re...
|
|
WO/2024/063569A1 |
A pharmaceutical composition for disrupting tumor blood vessels, according to an exemplary embodiment, may comprise alkaline 5-fluorouracil and a nitric oxide production inhibitor. For example, if the present invention includes alkaline ...
|
|
WO/2024/061390A1 |
The invention provides compounds of general formula (I) wherein each of X is CH or N, wherein at most one X is N; Y is CH or N; R1 is selected from H, halogen; R2 is selected from H, C1-C4 alkyl, C1-C4 alkylamino, C3-C6 cykloalkylamino; ...
|
|
WO/2024/062235A1 |
The present invention provides an antimicrobial combination comprising three different antimicrobial agents The first antimicrobial agent is selected from ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives...
|
|
WO/2024/062077A1 |
A composition comprising a phlorotannin or a α-fucan, or a combination thereof, for use in priming the endocrine system and enhancing insulin sensitivity, and for use in treating or preventing a disease or condition of an animal caused ...
|
|
WO/2024/062419A1 |
Chinese herbal formulations comprising at least one herb or a component thereof from three or more different classes of Chinese herbs selected from Blood tonifying, Blood moderators, Blood heat coolers, body heat coolers and Yang tonic a...
|
|
WO/2024/062395A1 |
The present disclosure relates to methods of treating metabolic conditions by administrating 5-methoxy-2-aminoindan, or a salt thereof, to a subject in need thereof in a therapeutically effective amount. The disclosure also relates to me...
|
|
WO/2024/063109A1 |
The purpose of the present invention is to provide a pharmaceutical composition and a senescent cell remover to be used in the treatment or prevention of NASH. The present invention is: a pharmaceutical composition for the treatment or p...
|
|
WO/2024/060864A1 |
The present invention relates to use of a competitive SNAT2 inhibitor or gene expression inhibition in preparing a medicament for preventing and/or treating hypertension. The competitive SNAT2 inhibitor is α-aminoisobutyric acid (MeAIB)...
|
|
WO/2024/062236A1 |
The present invention relates to a combination comprising at least four antimicrobial agents selected from rifampicin, levofloxacin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof....
|
|
WO/2024/063543A1 |
The present invention relates to a composition for treating cancer using combination therapy, comprising a Lactobacillus plantarum strain and herbal medicine. The Lactobacillus plantarum strain or a culture medium of the strain can not o...
|
|
WO/2024/063566A1 |
A pharmaceutical composition for the destruction of tumor blood vessels, according to an exemplary embodiment, may comprise alkaline 5-fluorouracil and glucose. For example, the composition comprises glucose and thus exerts a synergistic...
|
|
WO/2024/063546A1 |
The present invention relates to a pharmaceutical composition for cancer treatment through combined administration of a Lactobacillus plantarum strain and an anticancer drug. The Lactobacillus plantarum strain or a culture solution of th...
|
|
WO/2024/062423A1 |
The invention provides an oromucosal film composition comprising: a therapeutically effective amount of one or more active pharmaceutical ingredients selected from the group consisting of fluticasone, liraglutide, glucagone, midazolam, d...
|
|
WO/2024/058527A1 |
The present invention relates to a pharmaceutical composition for preventing or treating hearing loss comprising esomeprazole or dexlansoprazole as an active ingredient. As the effects of esomeprazole or dexlansoprazole on protecting hai...
|
|
WO/2024/056568A1 |
The present invention relates to a composition comprising cysteamine, azabenzene-4-carboxamide and glycolic acid. The present invention also relates to the cosmetic use thereof for inhibiting, reducing or preventing skin pigmentation and...
|
|
WO/2024/058252A1 |
A method according to the present invention is a method for predicting the therapeutic effect of pharmacotherapy in the treatment of a subject with metastatic prostate cancer, wherein the pharmacotherapy includes at least one selected fr...
|
|
WO/2024/058648A1 |
The present invention relates to a novel hyaluronidase PH-20 variant, and a use thereof, and more specifically, to: a hyaluronidase PH-20 variant selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4; a polyn...
|
|
WO/2024/057892A1 |
The present invention addresses the problem of providing a means for maintaining and enhancing the anti-tumor activity of TADC in a tumor microenvironment. It was found that when a composition, "cPLs adjuvant," containing three types o...
|
|
WO/2024/058077A1 |
Provided is a technology that can promote neuronal migration. This pharmaceutical composition for treating brain disease includes a neuraminidase inhibiting substance. This neuronal migration promoter includes a neuraminidase inhibiting ...
|
|
WO/2024/055534A1 |
The present application relates to pharmaceutical use of Radix Dipsaci-derived extracellular vesicle-like nanoparticles, and in particular to use of Radix Dipsaci-derived extracellular vesicle-like nanoparticles in the preparation of a d...
|
|
WO/2024/056995A1 |
The invention provides a combination of a PI3K/AKT/mTOR pathway inhibiting compound and a tanshinone or a derivative, an isomer or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/059829A1 |
Provided are compositions and methods for protecting tissue of patients undergoing radiation therapy from off-target radiation damage. The compositions comprise a compound selected from the group consisting of: glipizide, etidronate, mer...
|
|
WO/2024/056074A1 |
The present disclosure relates to a combination of an FAK inhibitor, a topoisomerase inhibitor, and an immune checkpoint inhibitor for use in treating a tumor. The present disclosure also relates to a combination of an FAK inhibitor and ...
|
|
WO/2024/058551A1 |
The present invention relates to: a pharmaceutical composition for the prevention or treatment of liver cancer, comprising cannabidiol (CBD) and an anticancer agent as active ingredients; and use thereof. The composition of the present i...
|
|
WO/2024/058065A1 |
A drug delivery composition comprising: a first particle that includes a first temperature responsive macromolecule and a first macromolecule having a first reactive functional group; and a second particle that includes a second temperat...
|
|
WO/2024/056659A1 |
The present invention relates to the treatment of cancer. Here, the inventors identified a subset of prostate cancer patients showing an up-regulation of the epigenetic enzymes SUV4-20H1 and SUV4-20H2, two methyltransferases responsible ...
|
|
WO/2024/056028A1 |
Provided are analgesic peptides. Also provided is a formulation comprising any one of the analgesic peptides and a pharmaceutically acceptable excipient. Also provided is a method for treating or preventing pain in a subject in need ther...
|
|
WO/2024/056791A1 |
The present invention concerns the compounds of formula (I) wherein R1, R2, R3, R4, X, Ar1 and Ar2 are as described in the description, and their use in the treatment of CFTR- related diseases and disorders, especially in the treatment o...
|
|
WO/2024/058093A1 |
According to the present invention, granules are prepared by combining a core containing an active ingredient with a coating layer coating the core. The granules can control the elution speed and lag time of the active ingredient accordi...
|
|
WO/2024/057304A1 |
The present disclosure generally relates to terpene -based vesicular delivery systems that are substantially phospholipid-free, and which are suitable for dermal and/or transdermal applications. The compositions provided by the invention...
|
|
WO/2024/059183A1 |
Provided herein are methods of treating cancer in a subject, the method comprising administering to the subject an agent that increases or stabilizes the activity or expression of PIEZO 1.
|
|
WO/2024/058427A1 |
A composition containing a steroid compound and a ginseng extract selected from the group consisting of a ginseng extract, a red ginseng extract, and a black ginseng extract as active ingredients provided by the present invention has a w...
|
|
WO/2024/058193A1 |
The present invention addresses the problem of providing a composition for an external preparation for skin, the composition: containing an ester-based steroid and gamma oryzanol, both the ester-based steroid component and the gamma oryz...
|
|
WO/2024/059353A1 |
This disclosure describes compositions including cannabinoids and omega fatty acids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer thera...
|
|
WO/2024/056716A1 |
Co-signaling immunotherapy, via immune checkpoint inhibitors (ICIs), such as ipilimumab (anti-CTLA-4) or nivolumab (anti-PD-1), has revolutionized cancer treatment. However, reinvigorating tumor-infiltrating T cell cytotoxicity has revea...
|
|
WO/2024/052698A1 |
The present invention relates to compositions, in particular to lipid-based compositions that solubilise and/or encapsulate (sometimes high concentrations of) copper complex(es) (and/or derivatives or analogues thereof). Such lipid-based...
|
|
WO/2024/052835A1 |
Methods for treating inflammation and conferring neuroprotection in the eye are provided, comprising the systemic and/or local administration of a variant of activated protein C (APC). Certain diseases, disorders or conditions caused dir...
|
|
WO/2024/053721A1 |
[Problem] To provide a therapeutic for spinal cord injury, especially severe spinal cord injury, from the acute phase to the subacute phase, the conventional treatment of which has been difficult. [Solution] A therapeutic for spinal cord...
|
|
WO/2024/053742A1 |
The present invention provides a pharmaceutical composition that comprises an IL-10 inhibitor and that is for use in the treatment or prevention of novel coronavirus (SARS-CoV-2) infection (COVID-19).
|
|
WO/2024/054807A1 |
Provided is a pharmaceutical composition including a metal channel activator and a TDP-43 modulator. Also provided is a method of treating a depressive disorder, including administering the pharmaceutical composition. Also provided is a ...
|
|
WO/2024/052914A1 |
The invention provides compositions comprising a modulator of a voltage dependent anion channel isoform VDAC1, 2 or 3 and methods for treating a group of rare autoimmune blistering skin conditions resulting from defective epidermal and m...
|
|
WO/2024/055048A1 |
The subject matter described herein relates to a method of treating or preventing prostate cancer in a subject with administration of a composition comprising a Nuclear Receptor Binding Set Domain Protein 2 (NSD2) inhibitor.
|
|
WO/2024/054527A1 |
A method of treating or preventing central nervous system cancer in a subject in need thereof is described. The method includes administering to the subject a therapeutically effective amount of myeloid cells modified to express interleu...
|
|
WO/2024/054944A1 |
Provided herein are methods, compositions, and uses involving T cell therapies, such as adoptive T cell therapy, and an inhibitor of a Diacylglycerol kinase (DGK). The provided methods, compositions, and uses include those involving the ...
|
